M&A Deal Summary

Vertex Pharmaceuticals Acquires Concert Pharmaceuticals - CTP-656

On March 6, 2017, Vertex Pharmaceuticals acquired life science company Concert Pharmaceuticals - CTP-656 from Concert Pharmaceuticals for 160M USD

Acquisition Highlights
  • This is Vertex Pharmaceuticals’ 3rd transaction in the Life Science sector.
  • This is Vertex Pharmaceuticals’ 6th largest (disclosed) transaction.
  • This is Vertex Pharmaceuticals’ 2nd transaction in the United States.
  • This is Vertex Pharmaceuticals’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2017-03-06
Target Concert Pharmaceuticals - CTP-656
Sector Life Science
Buyer(s) Vertex Pharmaceuticals
Sellers(s) Concert Pharmaceuticals
Deal Type Divestiture
Deal Value 160M USD

Target

Concert Pharmaceuticals - CTP-656

Lexington, Massachusetts, United States
Concert Pharmaceuticals, Inc. - CTP-656 was developed by Concert through the application of deuterium chemistry to modify Vertex’s CFTR potentiator, ivacaftor. Ivacaftor was discovered by Vertex scientists and is approved in the U.S., Europe, Canada and Australia for people with CF who have specific mutations in the CFTR gene. CTP-656 has the potential to play a key role in future once-daily combination regimens to treat CF. Concert is currently conducting a Phase 2 study of CTP-656 in people with CF who have gating mutations. As part of the agreement, Vertex will acquire rights to all of Concert’s other CF research and preclinical programs.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Vertex Pharmaceuticals

Boston, Massachusetts, United States
Category Company
Founded 1989
Sector Life Science
Employees5,400
Revenue 9.9B USD (2023)
DESCRIPTION

Vertex Pharmaceuticals is a biotechnology company that aims to discover, develop, and commercialize innovative new medicines so people with serious diseases can lead better lives. Vertex Pharmaceuticals was founded in 1989 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 3 of 8
Sector (Life Science) 3 of 8
Type (Divestiture) 1 of 2
State (Massachusetts) 1 of 3
Country (United States) 2 of 7
Year (2017) 1 of 1
Size (of disclosed) 6 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-07-26 Vertex Pharmaceuticals - Lomibuvir & Merimepodib Inhibitors

Boston, Massachusetts, United States

Vertex Pharmaceuticals - Lomibuvir & Merimepodib Inhibitors is a development and commercialization rights to treat infectious disease with lomibuvir (VX-222), a non-nucleoside inhibitor of the HCV NS5B polymerase and merimepodib (VX-497), an inhibitor of inosine monosphosphate dehydrogenase with broad-spectrum antiviral properties.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-06-06 Exonics Therapeutics

Watertown, Massachusetts, United States

Exonics Therapeutics, Inc. is developing gene editing therapies to treat patients with DMD and other severe genetic neuromuscular diseases and brings to Vertex intellectual property, technology, and scientific expertise in gene editing therapies for these serious diseases. In multiple small and large animal DMD preclinical models, Exonics has used SingleCut CRISPR to genetically repair and restore dystrophin, the key protein missing in children with DMD.

Buy $1.0B

Seller(S) 1

SELLER

Concert Pharmaceuticals

Lexington, Massachusetts, United States
Category Company
Founded 2006
Sector Life Science
Employees48
DESCRIPTION

Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor. The company has successfully completed two Phase 3 trials with deuruxolitinib in adults with Alopecia Areata, a serious autoimmune dermatological disease. It is also evaluating the use of deuruxolitinib in other indications and assessing a number of earlier-stage pipeline candidates. Concert Pharmaceuticals was founded in 2006 and is based in Lexington, Massachusetts.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Divestiture) 1 of 2
State (Massachusetts) 1 of 2
Country (United States) 1 of 2
Year (2017) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-03-11 Miuros

Lexington, Massachusetts, United States

Concert Pharmaceuticals' CNS therapeutics and accompanying intellectual property represent next-generation therapeutics with applications across several different psychiatric and neurological conditions. Concert Pharmaceuticals' CNS therapeutics and accompanying intellectual property is based in Lexington, Massachusetts.

Sell -
Mergr

Product

Company

Legal